Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000686099 | SCV000813602 | uncertain significance | MHC class I deficiency | 2023-08-17 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This sequence change replaces serine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 64 of the TAP1 protein (p.Ser64Phe). This variant is present in population databases (rs571573117, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with TAP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 566325). |
Ambry Genetics | RCV004965659 | SCV005511161 | uncertain significance | Inborn genetic diseases | 2024-09-18 | criteria provided, single submitter | clinical testing | The c.191C>T (p.S64F) alteration is located in exon 1 (coding exon 1) of the TAP1 gene. This alteration results from a C to T substitution at nucleotide position 191, causing the serine (S) at amino acid position 64 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |